

HCV/HIV COINFECTION
“New Drugs – New Challenges”

Dates: Monday, June 4 - Tuesday June 5 2012

Structure of the Cme course: Day I - from 9:30am through 06.30pm (UTC+1 Rome)
Day II - from 9am through 1pm (UTC+1 Rome)

Locations

Bologna: June 4 and 5, 2012 - for the entire duration of the event
Venue: Main hall at Johns Hopkins Bologna Center, Via Belmeloro 11.

Baltimore: June 4, 2012 - (8:30am / 12:15pm), US EST
Venue: Meeting Studio set at the Turner Building of the Johns Hopkins University Hospital.

Frankfurt: June 4, 2012 - (14:30pm / 18:30pm), UTC+1 Frankfurt
Venue : GMS Headquarters, Düsseldorf Str. 13 Eschborn, Frankfurt

Promoting Committee

G. Carosi (Brescia)
M. Puoti (Milano)
P. Viale (Bologna)

Scientific Committee

G. Carosi (Brescia)
M. Puoti (Milano)
A. Craxi (Palermo)
G. Verucchi (Bologna)

Expected Faculties

ITA (In addition to members of the above Committees)	USA	D
A. Alberti, Padova P. Andreoni Bologna M. Bernardi, Bologna L. Bolondi, Bologna R. Bruno, Pavia P. Caraceni, Bologna G. Carosi, Brescia M. Colombo, Milano S. Faggiuoli, Bergamo A.D. Pinna, Bologna M. Rizzetto, Torino A. Gasbarrini Roma M. Strazzabosco Monza	J.G. Bartlett, Baltimore C. Flexner, Baltimore D.T Dieterich, NY M. Sulkowski, Baltimore D. Thomas, Baltimore	J. Rockstroh, Bonn C. Sarrazin, Frankfurt S. Zeuzem, Frankfurt

Expected Program

[scheduled in Central European Time, except where printed in **blue color**]

Monday, June 4 2012

Registrations: 9:00am-9:30am

I Session: 9.30am –12.30pm

(Location: Bologna)

Front session with local contributions in the Main Hall of the Bologna Johns Hopkins Center.

Scheduled duration of presentations (apart from opening lectures): (15 min. + 5 min. discussions)

I Session HCV: From Natural History to Guidelines for anti-HCV therapies

Moderators G. Carosi e M. Rizzetto

- | | |
|---------------|---|
| 09.00 - 09.15 | Introduction
M. Rizzetto (Turin) |
| 10.15 -10.45 | Natural History of HCV Infection in patients with HIV infection:
from acute Hepatitis to Liver Transplant
G. Carosi (Brescia) |
| 10.45 -11.15 | Natural History of HCV Infection : from cirrhosis to Liver Transplant
S. Faggioli (Bergamo) |
| 11.15 -11.45 | EASL Guidelines : SOC in HCV G2-4
A. Craxì (Palermo) |
| 11.45 -12.15 | Anti HCV G1therapies: are AASLD guidelines applicable in Italy ?
A. Alberti (Padova) |
| 12.15 -12.45 | Antiviral Therapy with DAA in patients with Cirrhosis and HCV G1 infection
P. Andreone (Bologna) |

13.00 – 14.00 Lunch

IV Session: 14.30 - 18.15 (CET) **8.30am - 12.30pm (Us EST)**

Lectures and cross discussions in a **Videoconference between Bologna, Baltimore e Frankfurt.**

Scheduled duration of presentations (apart from opening lectures): (15 min. + 5 min. discussions)

Moderators PL Viale and M. Puoti

- | | |
|--------------------------------------|---|
| 14.30 -14.50
<i>8.30am-8.50am</i> | Viral Resistance to DAA
C.Sarrazin (Frankfurt) |
| 14.50 -15:10
<i>8.30am-9.10am</i> | DAA and clinical management of DDI
C. Flexner (Baltimore) |
| 15.10 -15.30
<i>9.10am-9.30am</i> | Data from clinical trials with Boceprevir in HIV uninfected patients
M. Sulkowski, Baltimore |
| 15.30 -15.50
<i>9.30am-9.50am</i> | Data from clinical trials with Telaprevir in HIV uninfected patients
D. Dietrich (New York) - or - K. Sherman (Cincinnati) |
| 15.50 -16.10 | Treatment of HCV-HIV co-infection |

9.50am-10.10am

J.Rockstroh (Bonn)

16.10 -16.30

Future perspective with DAA: three or four or one?

10.10am-10.30am

S.Zeuzem (Frankfurt)

16.30 -16.50

Lead in or not lead in

10.30am-10.50am

D. Thomas (Baltimore)

16.50 -17.50

Interactive cross debate between the three locations

10.50am-11.50am

Moderator: D. Thomas (Baltimore)

Topic: "Selection of patients for treatment : Who when and how

to treat"

17:50 -18.15

Conclusions

11.50 am-12..15pm

Tuesday, June 5

(Location: Bologna)

09.00- 11:00

II Session : Improvement of the Sanitary Expenditure for HCV
moderators **P. Caraceni (Bologna)**, **M. Bernardi (Bologna)**

Epidemiologic significance of HCV Infection in Italy

R. Bruno (Pavia)

Value Based Medicine and C Hepatitis

M. Strazzabosco (Monza)

Pharmacoeconomic approach to the utilization of new anti-HCV drugs

A. Cicchetti.(Roma)

From pharmacoeconomy and VBMH to affordability and Clinical Practice

A. Gasbarrini (Roma)

11:30-13:00

III Session : HIV-HCV Co-infections in special patients' populations

Moderators: L. Bolondi, (Bologna), A.D. Pinna (Bologna)

Treatment of the hemophilic patient with and without HIV Co-infection

M .Colombo (Milano)

Treatment of the HIV-HCV co-infected patient with cirrhosis

M. Puoti (Milano)

Anti-HCV Treatment of the HIV transplanted patient

G. Verrucchi (Bologna)